Identification of 2 distinct PR groups defined by 3-months BCR::ABL1% and high CD302 expression. (A) Decision tree selected 2 important variables 3-months BCR::ABL1% and CD302 gene expression to predict DMR (BCR::ABL1<0.0032% by 5 years). (B) Bar plot shows the proportion of patients treated with imatinib in PR-1, PR-2, and GR groups identified by the model using the discovery cohort. (C) Bar plot shows the proportion of patients treated with imatinib PR-1, PR-2, and GR groups identified by the model using the validation cohort. (D) Bar plot shows the proportion of patients treated with imatinib PR-1, PR-2, and GR groups identified by the model using the whole cohort. (E) Bar plot shows the proportion of patients treated with imatinib in high vs low CD302 gene expression using the threshold identified by the model on whole cohort. (F) The correlation between CD302 gene expression and CD302⁺ protein expression on CD45⁺ selected MNCs by flow cytometry. (G) Box plot shows the proportion CD302⁺ MNCs in patients treated with imatinib in PR-1, PR-2, and GR groups. (H) Bar plot shows the proportion of patients treated with nilotinib in high vs low CD302 gene expression based on median cutoff.